Resources > Articles

Regulatory Intelligence,
In Depth.

Articles, whitepapers, guides, and case studies for Life Sciences regulatory professionals navigating a faster, more complex regulatory world.

All Posts

Sep 305 min read

Pharma

A Drug Got Rejected Over a Factory Problem. The Fix Wasn't Fixing the Factory.

Sep 285 min read

Regulatory

The Cancer Test Everyone's Watching Just Got a Split Verdict

Sep 224 min read

Quality

Management Review Under QMSR: Why “Top Management” Now Means the CEO

Sep 224 min read

Regulatory

Combination Product Jurisdiction: How FDA Decides Who Reviews Your Product

Sep 224 min read

Quality

Supplier and Outsourcing Controls Under QMSR: The Audit Records Exemption Is Gone

Sep 224 min read

Regulatory

International Recognition and Reliance Pathways: The UK’s New Model for Device Access

Sep 224 min read

Quality

QMSR vs. QSR: What Actually Changed and What FDA Is Finding Five Months In

Sep 224 min read

Regulatory

Breakthrough Device Designation in 2026: What the Data Actually Shows

Sep 224 min read

Quality

Separating CAPA Workflows Under QMSR: What Manufacturers Actually Need to Change

Sep 224 min read

Regulatory

Predetermined Change Control Plans: How PCCPs Are Reshaping AI/ML Device Submissions

Sep 224 min read

Regulatory

Real-World Evidence in FDA Device Submissions: What Changed in 2026

Sep 224 min read

Regulatory

MDUFA VI Reauthorization: What It Means for Device Sponsors Through 2032

Sep 2210 min read

Regulatory

EU MDR Transition Deadlines: What Regulation 2023/607 Really Requires Before 2027

Sep 2210 min read

Regulatory

MDSAP in 2026: How the Single Audit Program Works After QMSR

Sep 229 min read

Quality

Risk Management Under QMSR: Why ISO 14971 Is Now the Center of FDA Inspections

Sep 228 min read

Quality

Design Controls Under QMSR: What Changes When 820.30 Becomes ISO 13485 Clause 7.3

Sep 220 min read

Regulatory

The EU AI Act and AI Medical Devices: What Changes Before August 2028

Sep 229 min read

Pharma

EU GMP Annex 1 Contamination Control Strategy: Building a CCS That Survives Inspection

Sep 228 min read

Pharma

ICH Q9(R1) in Practice: Formality, Subjectivity and What Inspectors Now Expect

Sep 229 min read

Pharma

CORE PLATFORM

BY INDUSTRY

BY ROLE

COMPANY

Resources > Articles

Regulatory Intelligence,
In Depth.

Get New Content Directly to your Inbox

All Posts

A Drug Got Rejected Over a Factory Problem. The Fix Wasn't Fixing the Factory.

The Cancer Test Everyone's Watching Just Got a Split Verdict

Management Review Under QMSR: Why “Top Management” Now Means the CEO

Combination Product Jurisdiction: How FDA Decides Who Reviews Your Product

Supplier and Outsourcing Controls Under QMSR: The Audit Records Exemption Is Gone

International Recognition and Reliance Pathways: The UK’s New Model for Device Access

QMSR vs. QSR: What Actually Changed and What FDA Is Finding Five Months In

Breakthrough Device Designation in 2026: What the Data Actually Shows

Separating CAPA Workflows Under QMSR: What Manufacturers Actually Need to Change

Predetermined Change Control Plans: How PCCPs Are Reshaping AI/ML Device Submissions

Real-World Evidence in FDA Device Submissions: What Changed in 2026

MDUFA VI Reauthorization: What It Means for Device Sponsors Through 2032

EU MDR Transition Deadlines: What Regulation 2023/607 Really Requires Before 2027

MDSAP in 2026: How the Single Audit Program Works After QMSR

Risk Management Under QMSR: Why ISO 14971 Is Now the Center of FDA Inspections

Design Controls Under QMSR: What Changes When 820.30 Becomes ISO 13485 Clause 7.3

The EU AI Act and AI Medical Devices: What Changes Before August 2028

EU GMP Annex 1 Contamination Control Strategy: Building a CCS That Survives Inspection

ICH Q9(R1) in Practice: Formality, Subjectivity and What Inspectors Now Expect

Nitrosamine and NDSRI Control After the August 2025 Deadline: Where FDA and EMA Stand

CORE PLATFORM

BY INDUSTRY

BY ROLE

COMPANY

Resources > Articles

Regulatory Intelligence, In Depth.

Get New Content Directly to your Inbox

All Posts

A Drug Got Rejected Over a Factory Problem. The Fix Wasn't Fixing the Factory.

The Cancer Test Everyone's Watching Just Got a Split Verdict

Management Review Under QMSR: Why “Top Management” Now Means the CEO

Combination Product Jurisdiction: How FDA Decides Who Reviews Your Product

Supplier and Outsourcing Controls Under QMSR: The Audit Records Exemption Is Gone

International Recognition and Reliance Pathways: The UK’s New Model for Device Access

QMSR vs. QSR: What Actually Changed and What FDA Is Finding Five Months In

Breakthrough Device Designation in 2026: What the Data Actually Shows

Separating CAPA Workflows Under QMSR: What Manufacturers Actually Need to Change

Predetermined Change Control Plans: How PCCPs Are Reshaping AI/ML Device Submissions

Real-World Evidence in FDA Device Submissions: What Changed in 2026

MDUFA VI Reauthorization: What It Means for Device Sponsors Through 2032

EU MDR Transition Deadlines: What Regulation 2023/607 Really Requires Before 2027

MDSAP in 2026: How the Single Audit Program Works After QMSR

Risk Management Under QMSR: Why ISO 14971 Is Now the Center of FDA Inspections

Design Controls Under QMSR: What Changes When 820.30 Becomes ISO 13485 Clause 7.3

The EU AI Act and AI Medical Devices: What Changes Before August 2028

EU GMP Annex 1 Contamination Control Strategy: Building a CCS That Survives Inspection

ICH Q9(R1) in Practice: Formality, Subjectivity and What Inspectors Now Expect

Nitrosamine and NDSRI Control After the August 2025 Deadline: Where FDA and EMA Stand

Regulatory Intelligence,
In Depth.